Further advancing one of the largest Phase III trials for head and neck
cancer in the world, CEL-SCI Corporation (NYSE MKT: CVM) announced
today that it has received approval from the Agency for Medicaments and
Medical Devices of the government of Bosnia and Herzegovina to begin
enrollment of subjects into the Phase III Head and Neck Cancer clinical
trial of its investigational cancer immunotherapy treatment Multikine*
(Leukocyte Interleukin, Injection). Bosnia and Herzegovina is the 10th
country into which CEL-SCI has now expanded its global Phase III trial.
This also marks the Company's milestone in receiving approval to
commence accrual in one-half the number of countries in the currently
planned expansion of the study. The trial is expected to expand into a
total
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in